HAS2 and prostate cancer: Co-immunofluorescent staining for HAS2 and LYVE-1 showed that a portion of prostate cancer cells that localized in the lymphatic vessels expressed dramatically higher levels of HAS2, with significant differences in the level of HAS2 in prostate cancer cells outside or inside the lymphatic vessels (Fig. 7f, g).